Inner ear disorder
diseaseOn this page
Also known as disease of internal eardisease or disorder of internal eardisorder of internal earinternal ear diseaseinternal ear disease or disorderinternal Ear disordervestibular disorder
Summary
Inner ear disorder (MONDO:0002467) is a disease (an umbrella term covering 15 Mondo subtypes) with 23 GWAS associations across 10 studies and 80 clinical trials. Top therapeutic interventions include betahistine and indoprofen. A subtype of auditory system disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Umbrella term: 15 Mondo subtypes
- GWAS associations: 23
- Clinical trials: 80
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | inner ear disorder |
| Mondo ID | MONDO:0002467 |
| EFO | EFO:0009672 |
| MeSH | D007759 |
| DOID | DOID:2952 |
| ICD-10-CM | H80-H83 |
| NCIT | C27166 |
| SNOMED CT | 232297009 |
| UMLS | C0494559 |
| MedGen | 141671 |
| Anatomy (UBERON) | UBERON:0001846 |
| Is cancer (heuristic) | no |
Also known as: disease of internal ear · disease or disorder of internal ear · disorder of internal ear · inner Ear disorder · internal ear disease · internal ear disease or disorder · internal Ear disorder · vestibular disorder
Data availability: 23 GWAS associations (10 studies).
Disease family
This is a subtype of auditory system disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › auditory system disorder › inner ear disorder
Related subtypes (10): discharging ear, dislocation of ear ossicle, adhesive otitis media, retrocochlear disease, external ear disorder, middle ear disorder, auditory system cancer, hearing disorder, inherited auditory system disease, auditory system benign neoplasm
Subtypes (15): bilateral hyperactive labyrinth, labyrinthine bilateral reactive loss, labyrinthitis, labyrinthine unilateral reactive loss, unilateral hyperactive labyrinth, vestibular disorder, cochlear disorder, bilateral hypoactive labyrinth, unilateral hypoactive labyrinth, otosclerosis, motion sickness, X-linked mixed hearing loss with perilymphatic gusher, autoimmune inner ear disease, enlarged vestibular aqueduct syndrome, inner ear neoplasm
Genetics & variants
GWAS landscape
23 GWAS associations across 10 studies. Top hits map to 0 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| chr19:23408594 | 7e-21 | T | 0.1 | |
| chr12:80305695 | 6e-15 | T | 0.14 | |
| chr4:4252541 | 2e-14 | G | 0.08 | |
| chr2:231268271 | 5e-12 | G | 0.07 | |
| chr8:133504369 | 7e-10 | A | 0.1 | |
| chr19:23513455 | 8e-10 | C | 0.09 | |
| chr10:117911974 | 4e-09 | T | 1.09 | |
| chr11:17583580 | 5e-09 | C | 0.07 | |
| chr8:71584487 | 7e-09 | T | 0.09 | |
| chr1:3149004 | 1e-08 | T | 0.06 | |
| chr11:121118626 | 1e-08 | G | 0.05 | |
| chr16:1595399 | 1e-08 | T | 1.91 | |
| chr11:30249097 | 2e-08 | T | 2.46 | |
| chr16:6823806 | 2e-08 | G | 0.49 | |
| chr7:143531856 | 2e-08 | G | 2.35 | |
| chr11:132799321 | 3e-08 | A | 3.26 | |
| chr5:20322416 | 3e-08 | C | 1.71 | |
| chr11:28697384 | 4e-08 | A | 2.94 | |
| chr1:165135161 | 4e-08 | C | 0.05 | |
| chr17:13628610 | 4e-08 | C | 1.7 | |
| chr1:204624755 | 4e-08 | ACC | 0.67 | |
| chr1:6007088 | 4e-08 | A | 0.82 | |
| chr12:80371375 | 5e-08 | T | 0.14 |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90473488 | UK Biobank Whole-Genome Sequencing Consortium | 2025 | 22,918 | 435,522 | Whole-genome sequencing of 490,640 UK Biobank participants. |
| GCST90667940 | UK Biobank Whole-Genome Sequencing Consortium | 2025 | 22,918 | 435,522 | Whole-genome sequencing of 490,640 UK Biobank participants. |
| GCST90473493 | UK Biobank Whole-Genome Sequencing Consortium | 2025 | 11,436 | 447,004 | Whole-genome sequencing of 490,640 UK Biobank participants. |
| GCST90667857 | UK Biobank Whole-Genome Sequencing Consortium | 2025 | 11,436 | 447,004 | Whole-genome sequencing of 490,640 UK Biobank participants. |
| GCST90079945 | Backman JD | 2021 | 2,745 | 377,741 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90083931 | Backman JD | 2021 | 2,745 | 377,741 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90726875 | Kim HI | 2026 | 1,186 | 42,840 | Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity. |
| GCST90473489 | UK Biobank Whole-Genome Sequencing Consortium | 2025 | 463 | 9,150 | Whole-genome sequencing of 490,640 UK Biobank participants. |
| GCST90473487 | UK Biobank Whole-Genome Sequencing Consortium | 2025 | 249 | 8,966 | Whole-genome sequencing of 490,640 UK Biobank participants. |
| GCST90473494 | UK Biobank Whole-Genome Sequencing Consortium | 2025 | 237 | 9,376 | Whole-genome sequencing of 490,640 UK Biobank participants. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 23 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 0 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 0 |
| unknown | 23 |
Functional consequences
| Consequence | Count |
|---|---|
| unknown | 23 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| chr19:23408594 | 7e-21 | Tier 4: intronic/intergenic | ||||||
| chr12:80305695 | 6e-15 | Tier 4: intronic/intergenic | ||||||
| chr4:4252541 | 2e-14 | Tier 4: intronic/intergenic | ||||||
| chr2:231268271 | 5e-12 | Tier 4: intronic/intergenic | ||||||
| chr8:133504369 | 7e-10 | Tier 4: intronic/intergenic | ||||||
| chr19:23513455 | 8e-10 | Tier 4: intronic/intergenic | ||||||
| chr10:117911974 | 4e-09 | Tier 4: intronic/intergenic | ||||||
| chr11:17583580 | 5e-09 | Tier 4: intronic/intergenic | ||||||
| chr8:71584487 | 7e-09 | Tier 4: intronic/intergenic | ||||||
| chr1:3149004 | 1e-08 | Tier 4: intronic/intergenic | ||||||
| chr11:121118626 | 1e-08 | Tier 4: intronic/intergenic | ||||||
| chr16:1595399 | 1e-08 | Tier 4: intronic/intergenic | ||||||
| chr11:30249097 | 2e-08 | Tier 4: intronic/intergenic | ||||||
| chr16:6823806 | 2e-08 | Tier 4: intronic/intergenic | ||||||
| chr7:143531856 | 2e-08 | Tier 4: intronic/intergenic | ||||||
| chr11:132799321 | 3e-08 | Tier 4: intronic/intergenic | ||||||
| chr5:20322416 | 3e-08 | Tier 4: intronic/intergenic | ||||||
| chr11:28697384 | 4e-08 | Tier 4: intronic/intergenic | ||||||
| chr1:165135161 | 4e-08 | Tier 4: intronic/intergenic | ||||||
| chr17:13628610 | 4e-08 | Tier 4: intronic/intergenic | ||||||
| chr1:204624755 | 4e-08 | Tier 4: intronic/intergenic | ||||||
| chr1:6007088 | 4e-08 | Tier 4: intronic/intergenic | ||||||
| chr12:80371375 | 5e-08 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 80.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 80 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03799991 | Not specified | RECRUITING | Vestibular Therapy in Alzheimer’s Disease |
| NCT04685746 | Not specified | RECRUITING | BALANCED GROWTH: The Involvement of the Vestibular System in a Child’s Cognitive and Motor Development |
| NCT05322538 | Not specified | NOT_YET_RECRUITING | Menier’s Disease - Bone Density Study |
| NCT05414903 | Not specified | RECRUITING | Reading Outcomes in Children With Vestibular Loss |
| NCT05622344 | Not specified | RECRUITING | StableEyes With Active Neurofeedback |
| NCT05831618 | Not specified | NOT_YET_RECRUITING | New Rehabilitation Protocol for Patients With PPPD |
| NCT05942781 | Not specified | ACTIVE_NOT_RECRUITING | Concurrent Vestibular Activation and Postural Training Using Virtual Reality |
| NCT06177132 | Not specified | NOT_YET_RECRUITING | Vestibular Infant Screening - Rehabilitation |
| NCT06229704 | Not specified | RECRUITING | Vestibular and Postural Function in Children Suspected of Balance Disorders |
| NCT06229717 | Not specified | RECRUITING | Vestibular and Postural Function in an Unselected Group of Children With Sensorineural Hearing Loss |
| NCT06683417 | Not specified | NOT_YET_RECRUITING | Effectiveness of VestAid App |
| NCT06688578 | Not specified | RECRUITING | Testing Effectiveness of a Stochastic Noise Stimulator to Immediately Improve Balance and Gait |
| NCT07079488 | Not specified | ENROLLING_BY_INVITATION | Vestibular Function and Motor Development in Small Children |
| NCT07081542 | Not specified | NOT_YET_RECRUITING | Comparative Analysis of Hearing Outcomes: Robotic vs. Manual Insertion of Cochlear Implants |
| NCT07238387 | Not specified | NOT_YET_RECRUITING | Evaluation of Nystagmus Examination Using Wearable AR Glasses in Vertigo Patients |
| NCT07267910 | Not specified | NOT_YET_RECRUITING | Measuring Vestibular Organ Function With Weak Alternating Current Stimulation |
| NCT07559162 | Not specified | NOT_YET_RECRUITING | Ai Chi-Based Rehabilitation for Peripheral Unilateral Vestibular Dysfunction |
| NCT07575074 | Not specified | NOT_YET_RECRUITING | OKT With Gaze and Postural Stabilization on Vertigo, MS and QOL in VBH |
| NCT01399671 | Not specified | COMPLETED | Study of the Effectiveness of Vestibular Stimulation as a Coadjuvant Treatment in Major Depression |
| NCT02072460 | Not specified | UNKNOWN | Vestibular and Multisensory Influence on Bodily and Spatial Representations |
| NCT02735096 | Not specified | TERMINATED | Testing an Intraoral Electronic Balance Aid for Vestibular Imbalance |
| NCT02746770 | Not specified | UNKNOWN | Physiotherapy in Vestibular Disorders |
| NCT03163901 | Not specified | COMPLETED | The Effect of OMT on Functional Outcomes and Anti-inflammatory Biomarkers in Mild to Moderate Traumatic Brain Injury |
| NCT03330262 | Not specified | COMPLETED | Head-Mounted Vibrotactile Prosthesis for Patients With Chronic Postural Instability |
| NCT03417596 | Not specified | COMPLETED | Vestibular Rehabilitation in Patients With Vestibular Migraine |
| NCT03421847 | Not specified | COMPLETED | Study of Rotatory Vestibular Tests in Major Depression Patients and Healthy Control Subjects. |
| NCT03431506 | Not specified | UNKNOWN | Vestibular Function and Vestibular Rehabilitation in SSHL With Vertigo |
| NCT03446677 | Not specified | COMPLETED | Postural Stability Deficiencies in Asymptomatic Individuals With HIV |
| NCT03555370 | Not specified | COMPLETED | Vestibular Treatment in Adolescents Following Sport Related Concussion |
| NCT03579186 | Not specified | WITHDRAWN | OKS for Gait Instability |
| NCT03600324 | Not specified | COMPLETED | Randomized Controlled Trial for Vestibular Treatment in Concussion |
| NCT03624283 | Not specified | UNKNOWN | Interventions for Residual Dizziness After Successful Repositioning Maneuvers in Patients With BPPV |
| NCT03677661 | Not specified | COMPLETED | Cervico-vestibular Rehabilitation for Mild Traumatic Brain Injury |
| NCT03690817 | Not specified | UNKNOWN | Hearing Loss, Vestibular Loss and Cognitive Performance |
| NCT03826056 | Not specified | COMPLETED | Neurology Inpatient Clinical Education Trial |
| NCT03915353 | Not specified | COMPLETED | Evaluation Of Vestibular Functions and Balance in Edirne Band Musicians |
| NCT03951584 | Not specified | COMPLETED | Prognosis of Vestibular Dysfunction in Patients With Idiopathic Sudden Sensorineural Hearing Loss |
| NCT03952936 | Not specified | COMPLETED | Vestibular Rehabilitation for Chronic Central Vestibular Deficits: A Case Study |
| NCT03957044 | Not specified | COMPLETED | the Effect of Vestibular Rehabilitation in Autistic Children |
| NCT04053829 | Not specified | UNKNOWN | Feasibility and Acceptability of HOLOBalance Compared to Standard Care in Older Adults at Risk for Falls |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| BETAHISTINE | 4 | 1 |
| INDOPROFEN | 4 | 1 |
| CHEMBL443232 | 0 | 2 |
| BETAHISTINE MESILATE | -1 | 1 |
Related Atlas pages
- Drugs: Betahistine, Indoprofen